| I-48 Satoshi Shoji Population Pharmacokinetic Analysis of Tanezumab, a Novel Monoclonal Antibody to Nerve Growth Factor, Following Intravenous or Subcutaneous Administration to Patients with Osteoarthritis or Chronic Low Back Pain in Phase 2b and Phase 3 Studies |
| I-49 Satoshi Shoji Prediction of Free Target Suppression Following Subcutaneous Administration of Tanezumab Based on Target-mediated Drug Disposition Approximation Model |
